@article {MORITA909, author = {MASARU MORITA and AKINORI EGASHIRA and YU NAKAJI and MASAKI KAGAWA and MASAHIKO SUGIYAMA and DAISUKE YOSHIDA and MITSUHIKO OTA and MASAHIKO IKEBE and MUNEYUKI MASUDA and YOJIRO INOUE and NAONOBU KUNITAKE and YASUSHI TOH}, title = {Treatment of Squamous Cell Carcinoma of the Esophagus Synchronously Associated with Head and Neck Cancer}, volume = {31}, number = {5}, pages = {909--916}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The aim of this study was to clarify the treatment strategy for synchronous squamous cell carcinoma of the esophagus (ESCC) and head and neck cancer (HNC). Patients and Methods: Treatment outcomes of 91 patients with synchronous ESCC and HNC were evaluated. Thirty-eight patients received simultaneous definitive chemoradiotherapy (CRT) and 15 patients underwent simultaneous resection. Results: Among the patients who received simultaneous CRT, adverse events (grade 3-5) were recognized in 14 patients (40\%), including one case of death due to aspiration pneumonia. Complete response was observed in 22 patients with ESCC (58\%) and 19 patients with HNC (50\%). The five-year survival rate was 44\%. There were no in-hospital deaths after simultaneous resection; however, postoperative complications were recognized in 4 patients. The five-year OS was 70\%. Conclusion: The treatment of synchronous ESCC and HNC must be decided by adopting a strategy that is appropriate for each case. Both simultaneous CRT and simultaneous resection are feasible and effective treatment options.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/31/5/909}, eprint = {https://iv.iiarjournals.org/content/31/5/909.full.pdf}, journal = {In Vivo} }